The role of soy isoflavones in menopausal health: Report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010)

Menopause

Volumn 18, Issue 7, 2011, Pages 732-753

  Clarkson, Thomas B ^a   Utian, Wulf H ^a   Barnes, Stephen ^a   Gold, Ellen B ^a   Basaria, Shehzad S ^a   Aso, Takeshi ^a   Kronenberg, Fredi ^a   Frankenfeld, Cara L ^a   Cline, J M Ark ^a   Landgren, Britt Marie ^a   Gallagher, J Chris ^a   Weaver, Connie M ^a   Hodis, Howard N ^a   Brinton, Roberta Diaz ^a   Maki, Pauline M ^a   Setchell, Kenneth D R ^a   Setchell, D R ^a   Allmen, Tara I ^a   Messina, Mark J ^a   Shu, Xiao Ou ^a   Ishimi, Yoshiko ^a   Wong, William W ^a   Kim, Helen ^a   more..

^a North American Menopause Society   (United States)

Author keywords

Daidzein; Equol; Equol nonproducer; Equol producer; Estrogen receptor ; Estrogen receptor A; Genistein; Glycitein; Glycoside; Phytoestrogen; R(+) equol; S(Y) equol; Soy; Soy germ; Soy isoflavone; Soy protein; Soy supplement.; Words: Aglycone

Indexed keywords

AGLYCONE; ALKALINE PHOSPHATASE; DAIDZEIN; EQUOL; GENISTEIN; GLYCITEIN; ISOFLAVONE DERIVATIVE; PLACEBO; PUERARIN; SOY ISOFLAVONE; SOYBEAN OIL; SOYBEAN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR EFFECT; CHINA; CLIMACTERIUM; CLINICAL RESEARCH; COGNITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENDOMETRIUM CANCER; FOOD INTAKE; GENERAL PRACTICE; HUMAN; JAPANESE; MEDICAL SOCIETY; MENOPAUSE; METABOLITE; NONHUMAN; NORTH AMERICA; OSTEOBLAST; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SOYBEAN; SOYBEAN MILK; UNITED STATES; VAGINAL DRYNESS; WOMEN'S HEALTH;

BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; ISOFLAVONES; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; SOYBEAN PROTEINS; SOYBEANS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 79959723419     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31821fc8e0     Document Type: Article

References (231)

1. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5595.
2. Hill TD, Dean NM, Mordan LJ, Lau AF, Kanemitsu MY, Boynton AL. PDGF-induced activation of phospholipase C is not required for induction of DNA synthesis. Science 1990;248:1660-1663.
3. Boersma BJ, D'Alessandro T, Benton MR, et al. Neutrophil myeloperoxidase chlorinates and nitrates soy isoflavones and enhances their antioxidant properties. Free Radic Biol Med 2003;35:1417-1430. (Pubitemid 37452467)
4. D'Alessandro T, Prasain J, Benton MR, et al. Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J Nutr 2003;133:3773S-3777S. (Pubitemid 37392599)
5. Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-rastransformed NIH 3T3 cells. Biochem Biophys Res Commun 1988;157: 183-189. (Pubitemid 19004843)
6. Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett 1998;133:101-106. (Pubitemid 29069117)
7. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005;94:461-467. (Pubitemid 40616407)
8. Klein CB, King AA. Genisteingenotoxicity: critical considerations of in vitro exposure dose. Toxicol Appl Pharmacol 2007;224:1-11. (Pubitemid 47404623)
9. Sun Q, Cong R, Yan H, et al. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep 2009;22:563-567.
10. Parker LP, Taylor DD, Kesterson J, Metzinger DS, Gercel-Taylor C. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur J Gynaecol Oncol 2009;30:616-621.
11. Li Y, Vandenboom TG 2nd, Wang Z, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010;70:1486-1495.
12. Zaman MS, Chen Y, Deng G, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010;103:256-264.
13. Majid S, Dar AA, Saini S, et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res 2010;70:2809-2818.
14. Muthyala RS, Ju YH, Sheng S, et al. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004;12: 1559-1567. (Pubitemid 38304880)
15. Barnes S. Mechanisms of Action of Isoflavones in Cancer Prevention. In: Milner JA, Romagnolo D, eds. Bioactive Compounds and Cancer. Totowa, NJ: Springer-Verlag, 2010:633-670.
16. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483-488. (Pubitemid 32701634)
17. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-1496. (Pubitemid 35012429)
18. Korde LA, Wu AH, Fears T, et al. Childhood soy intake and breast cancer risk in Asian American women. Cancer Epidemiol Biomarkers Prev 2009;18:1050-1059.
19. Penetar DM, Teter CJ, Ma Z, Tracy M, Lee DY, Lukas SE. Pharmacokinetic profile of the isoflavone puerarin after acute and repeated administration of a novel kudzu extract to human volunteers. J Altern Complement Med 2006;12:543-548. (Pubitemid 44689677)
20. Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in young women: importance of the chemical composition of soyabean products. Br J Nutr 1995;74:587-601.
21. Watanabe S, Yamaguchi M, Sobue T, et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 1998;128:1710-1715. (Pubitemid 28452856)
22. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. Pharmacokinetics of the glucorinide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 2002;76:588-594. (Pubitemid 34920836)
23. Cassidy A, Brown JE, Hawdon A, et al. Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr 2006;136:45-51. (Pubitemid 43156483)
24. King R, Bursill D. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 1998;67:867-872. (Pubitemid 28196660)
25. Izumi T, Piskula M, Osawa S, et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 2000;130:1695-1699. (Pubitemid 30451055)
26. Richelle M, Pridmore-Merten S, Bodenstab S, Enslen M, Offord EA. Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women. J Nutr 2002;132:2587-2592. (Pubitemid 35013238)
27. Gardner CD, Chatterjee LM, Franke AA. Effects of isoflavone supplements vs soy foods on blood concentrations of genistein and daidzein in adults. J Nutr Biochem 2009;20:227-234.
28. Vergne S, Sauvant P, Lamothe V, et al. Influence of ethnic origin (Asian v Caucasian) and background diet on the bioavailability of dietary isoflavones. Br J Nutr 2009;102:1642-1653.
29. Franke AA, Halm BM, Ashburn LA. Isoflavones in children and adults consuming soy. Arch Biochem Biophys 2008;476:161-170.
30. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126-136. (Pubitemid 34013498)
31. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr 2002;76:1126-1137. (Pubitemid 35244688)
32. Takimoto CH, Glover K, Huang X, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarker Preven 2003;12(11 Pt 1):1213-1221. (Pubitemid 37499447)
33. Zubik L, Meydani M. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am J Clin Nutr 2003;77:1459-1465. (Pubitemid 39655280)
34. Setchell KD, Brown NM, Desai PB, et al. Bioavailablity, disposition, and dose response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 2003;133: 1027-1035. (Pubitemid 36407120)
35. Setchell KD, Brzezinski A, Brown NM, et al. Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women. J Agric Food Chem 2005;53:1938-1944. (Pubitemid 40395758)
36. Vergne S, Titier K, Bernard V, et al. Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production. J Pharm Biomed Anal 2007;43: 1488-1494.
37. Setchell KD, Zhao X, Shoaf SE, Ragland K. The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women. J Nutr 2009;139:2037-2043.
38. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131(Suppl 4):1362S-1375S. (Pubitemid 32268489)
39. Setchell KDR, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor b, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-1079. (Pubitemid 41724948)
40. Setchell KD, Faughnan MS, Avades T, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr 2003;77:411-419. (Pubitemid 36133385)
41. Setchell KDR, Zhao X, Jha P, Heubi JE, Brown NM. The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stableisotope- labeled tracers. Am J Clin Nutr 2009;90:1029-1037.
42. Setchell KDR, Clerici C. Equol: history, chemistry, and formation. J Nutr 2010;140:1355S-1362S.
43. Day AJ, DuPont MS, Ridley S, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver betaglucosidase activity. FEBS Letters 1998;436:71-75. (Pubitemid 28454609)
44. Fanti P, Sawaya BP, Custer LJ, Franke AA. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J Am Soc Nephrol 1999;10:864-871. (Pubitemid 29149538)
45. Song T, Hendrich S, Murphy P. Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem 1999;47:1607-1610. (Pubitemid 29217165)
46. Setchell KD, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr 2010;140:1363S-1368S.
47. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 1984;40:569-578. (Pubitemid 14035518)
48. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998;217:335-339.
49. Setchell KD, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr 2006;136:2188-2193. (Pubitemid 44156823)
50. Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equolYa clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-3584. (Pubitemid 35435031)
51. Klein MA, Nahin RL, Messina MJ, et al. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr 2010;140:1192S-1204S.
52. Sfakianos J, Coward L, Kirk M, Barnes S. Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J Nutr 1997;127: 1260-1268. (Pubitemid 27283989)
53. Nagel SC, vom Saal FS, Welshons WV. The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: physiology of delivery modifies estrogenic activity. Proc Soc Exp Biol Med 1998;217:300-309.
54. Kurzer M. Phytoestrogen supplement use by women. J Nutr 2003;133: 1983S-1986S. (Pubitemid 36666547)
55. Franke AA, Custer LJ, Wang W, Shi CY. HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. Proc Soc Exp Biol Med 1998;217:263-273.
56. Wang SW, Chen Y, Joseph T, Hu M. Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. J Altern Complement Med 2008; 14:287-297. (Pubitemid 351519560)
57. US Department of Agriculture. USDA Database for the Isoflavone Content of Selected Foods, 2.0. 2008. Available at: http://www.ars.usda.gov/ is/pr/2008/080923.htm. Accessed April 6, 2011.
58. Messina M. A brief historical overview of the past two decades of soy and isoflavone research. J Nutr 2010;140:1350S-1354S.
59. Soyfoods Association of North America. The U.S. Market 2010. Available at: http://www.soyfoods.org/products/sales-and-trends. Accessed March 21, 2011.
60. Mintel International Group. Soy-based Food and DrinkYUSYDecember .2008. Available at: http://oxygen.mintel.com/sinatra/oxygen/display/ id=297947. Accessed April 6, 2011.
61. Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a populationbased survey. Obstet Gynecol 2002;100:18-25. (Pubitemid 34722839)
62. Huang M-H, Schocken M, Block G, et al. Variation in nutrient intakes by ethnicity: results from the Study of Women's Health Across the Nation (SWAN). Menopause 2002;9:309-319. (Pubitemid 36701890)
63. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006;55:1-12. (Pubitemid 44477039)
64. Nagata C, Takatsuka N, Kurisu Y, Shimizu H. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. J Nutr 1998;128:209-213. (Pubitemid 28124988)
65. Nagata C, Takatsuka N, Kawakami N, Shimizu H. Association of diet with the onset of menopause in Japanese women. Am J Epidemiol 2000;152:863-867.
66. Nagata C, Takatsuka N, Kawakami N, Shimizu H. A prospective cohort study of soy product intake and stomach cancer death. Br J Cancer 2002;87:31-36.
67. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. Soy product intake is inversely associated with serum homocysteine level in premenopausal Japanese women. J Nutr 2003;133:797-800. (Pubitemid 36268357)
68. Takata Y, Maskarinec G, Franke A, Nagata C, Shimizu H. A comparison of dietary habits among women in Japan and Hawaii. Public Health Nutr 2004;7:319-326. (Pubitemid 38419618)
69. Nagata C, Nakamura K, Oba S, Hayashi M, Takeda N, Yasuda K. Association of intakes of fat, dietary fibre, soya isoflavones and alcohol with uterine fibroids in Japanese women. Br J Nutr 2009;101:1427-1431.
70. Akhter M, Inoue M, Kurahashi N, et al. Dietary soy and isoflavone intake and risk of colorectal cancer in the Japan public health centerbased prospective study. Cancer Epidemiol Biomarkers Prev 2008;17: 2128-2135.
71. Shimazu T, Inoue M, Sasazuki S, et al. Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. Am J Clin Nutr 2010;91:722-728.
72. Yang G, Shu XO, Jin F, et al. Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Am J Clin Nutr 2005;81:1012-1017. (Pubitemid 41724941)
73. Yang G, Shu XO, Li H, et al. Prospective cohort study of soy food intake and colorectal cancer risk in women. Am J Clin Nutr 2009;89:577-583.
74. Lee SA, Wen W, Xiang YB, et al. Assessment of dietary isoflavone intake among middle-aged Chinese men. J Nutr 2007;137:1011-1016. (Pubitemid 46596902)
75. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;343:1-19.
76. Upchurch DM, Chyu L, Greendale GA, et al. Complementary and alternative medicine use among American women: Findings from The National Health Interview Survey, 2002. J Women's Health 2007;16: 102-113.
77. Upchurch DM, Dye CE, Chyu L, Gold EB, Greendale GA. Demographic, behavioral, and health correlates of complementary and alternative medicine and prayer use among midlife women: 2002. J Women's Health (Larchmt) 2010;19:23-30.
78. Upchurch DM, Chyu L. Use of complementary and alternative medicine among American women. Womens Health Issues 2005;15:5-13. (Pubitemid 40127480)
79. Graham RE, Ahn AC, Davis RB, O'Connor BB, Eisenberg DM, Phillips RS. Use of complementary and alternative medical therapies among racial and ethnic minority adults: Results from the 2002 National Health Interview Survey. J Natl Med Assoc 2005;97:535-545. (Pubitemid 40463583)
80. Kronenberg F, Cushman LF, Wade CM, Kalmuss D, Chao MT. Race/ ethnicity and women's use of complementary and alternative medicine in the United States: results of a national survey. Amer J Public Health 2006;96:1236-1242. (Pubitemid 43967849)
81. Rossouw JE, Anderson GL, Prentice RL, et al, for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
82. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, Aloysio DD. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6-11. (Pubitemid 28042324)
83. Basaria S, Wisniewski A, Dupree K, et al. Effect of high-dose isoflavones on cognition, quality of life, androgens, and lipoprotein in postmenopausal women. J Endocrinol Invest 2009;32:150-155.
84. Burke GL, Legault C, Anthony M, et al. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause 2003;10:147-153. (Pubitemid 36702702)
85. Cheng G, Wilczek B, Warner M, Gustafsson J-A, Landgren B-M. Isoflavone treatment for acute menopausal symptoms. Menopause 2007;14:468-473.
86. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause 2004;11:400-404. (Pubitemid 40372093)
87. D'Anna R, Cannata ML, Martini H, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebocontrolled study. Menopause 2009;16:301-306.
88. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a mutlicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9:329-334. (Pubitemid 36701892)
89. Han KK, Soares JM, Haidar MA, Rodrigues de Lima G, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002;99:389-394. (Pubitemid 34188398)
90. Khaodhiar L, Ricciotti HA, Linglin L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008;15:125-132.
91. Nahas EP, Neto JN, De Luca L, Traiman P, Pontes A, Dalben I. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 2004;48:372-380. (Pubitemid 38993251)
92. Penotti M, Fabio E, Modena AB, Rinaldi M, Omodei U, Vigano P. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril 2003;79:1112-1117. (Pubitemid 36547847)
93. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000;7:105-111. (Pubitemid 30151397)
94. St. German A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001;8:17-26. (Pubitemid 32066576)
95. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebocontrolled study. Menopause 2000;7:236-242. (Pubitemid 30445953)
96. Messina M, Hughes C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food 2003;6:1-11. (Pubitemid 36576609)
97. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published papers. Menopause 2006;13:831-839. (Pubitemid 44435039)
98. Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr 2010;140:1386S-1389S.
99. Jou HJ, Wu SC, Chang FW, Ling PY, Chu KS, Wu WH. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet 2008;102:44-49.
100. Ishiwata N, Melby MK, Mizuno S, Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 2009;16:141-148.
101. Jenks B, Uchiyama S, Iwashita S, et al. Abstract P-22: Efficacy and safety of natural S-equol supplement in US postmenopausal women. 21st Annual Meeting of The North American Menopause Society. Menopause 2010;17:1229.
102. Nikander E, Rutanen EM, Nieminen P, Wahlstrom T, Ylikorkala O, Tiitinen A. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertil Steril 2005;83:137-142. (Pubitemid 40094792)
103. Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994;49:153-160. (Pubitemid 24237089)
104. Scott LM, Xu X, Veenstra TD, et al. Past oral contraceptive use and current dietary soy isoflavones influence estrogen metabolism in postmenopausal monkeys (Macaca fascicularis). Cancer Epidemiol Biomarkers Prev 2008a;17:2594-2602.
105. Scott LM, Durant P, Leone-Kabler S, et al. Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes. J Steroid Biochem Mol Biol 2008;112:179-185.
106. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 1991;179:661-677.
107. Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E. Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Cell Growth Differ 1994;5:995-1004. (Pubitemid 24275114)
108. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1995;125:790S-797S.
109. Kim MH. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 2003;89: 529-538. (Pubitemid 36648774)
110. Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ. Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci 2003;94:215-220. (Pubitemid 36575884)
111. Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res 2006;66:1241-1249. (Pubitemid 43165996)
112. Wood CE, Register TC, Cline JM. Soy isoflavonoid effects on endogenous estrogen metabolism in postmenopausal female monkeys. Carcinogenesis 2007;4:801-808. (Pubitemid 46523336)
113. Lamartiniere CA, Murrill WB, Manzolillo PA, et al. Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc Soc Exp Biol Med 1998;217:358-364.
114. Lamartiniere CA, Wang J, Smith-Johnson M, Eltoum IE. Daidzein: bioavailability, potential for reproductive toxicity, and breast cancer chemoprevention in female rats. Toxicol Sci 2002;65:228-238. (Pubitemid 34121115)
115. Brown NM, Belles CA, Lindley SL, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis 2010;31:886-893.
116. Brown NM, Belles CA, Lindley SL, et al. Mammary gland differentiation by early life exposure to the enantiomers of the soy isoflavone metabolite equol. Food Chem Toxicol 2010;48:3042-3050.
117. Wang TT, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996;17: 271-275. (Pubitemid 26091305)
118. Terasaka S, Aita Y, Inoue A, et al. Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect 2004;112:773-781. (Pubitemid 38720158)
119. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L. The role of early life genistein exposures in modifying breast cancer risk. Br J Cancer 2008;98:1485-1493. (Pubitemid 351652325)
120. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 2000;71:1705S-1707S.
121. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Research 1998;58: 3833-3838. (Pubitemid 28405638)
122. Allred CD, Allred KF, Ju YH, et al. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 2004;25:211-218. (Pubitemid 38239804)
123. Magee PJ, Raschke M, Steiner C, et al. Equol: a comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity in breast and prostate cells in vitro. Nutr Cancer 2006;54:232-242. (Pubitemid 44316306)
124. Lampe JW. Emerging research on equol and cancer. J Nutr 2010;140: 1369S-1372S.
125. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005;230:155-170. (Pubitemid 40293689)
126. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006;98:459-471.
127. Wu AH, Yu MC, Tseng CC. Pike MC Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008a;98:9-14.
128. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters HM. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007;25:648-655. (Pubitemid 350002919)
129. Nishio K, Niwa Y, Toyoshima H, et al. Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study. Cancer Causes Control 2007;18:801-808. (Pubitemid 47125111)
130. Iwasaki M, Inoue M, Otani T, et al; for the Japan Public Health Centerbased prospective study group. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008;26:1677-1683.
131. Wu AH, Koh WP, Wang R, Lee HP, Yu MC. Soy intake and breast cancer risk in Singapore Chinese Health study. Br J Cancer 2008;99: 196-200. (Pubitemid 351920241)
132. Lee SA, Shu XO, Li H, et al. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr 2009;89:1920-1926.
133. Goodman MT, Shvetsov VB, Wilkens LR, et al. Urinary phytoestrogen excretion and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Prev Res 2009;2:887-892.
134. Suzuki T, Matsuo K, Tsunoda N, et al. Effect of soybean on breast cancer according to receptor status: a case-control study in Japan. Int J Cancer 2008;123:1674-1680.
135. Cho YA, Kim J, Park KS, et al. Effect of dietary soy intake on breast cancer risk according to menopause and hormone receptor status. Eur J Clin Nutr 2010;64:924-932.
136. Zhang C, Ho SC, Lin F, Cheng S, Fu J, Chen Y. Soy product and isoflavone intake and breast cancer risk defined by hormone receptor status. Cancer Sci 2010;101:501-507.
137. Zhang CX, Ho SC, Fu JH, Cheng SZ, Chen YM, Lin FY. Dietary patterns and breast cancer risk among Chinese women. Cancer Causes Control 2010;22:115-124.
138. Thanos J, Cotterchio M, Boucher BA, Kreiger N, Thompson LU. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 2006;17:1253-1261. (Pubitemid 44772825)
139. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008;7:17.
140. Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. JAMA 2009;302:2437-2443.
141. Guha N, Kwan ML, Quesenberry CP Jr, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 2009;118:395-405.
142. Kang X, Zhang Q, Wang S, Huang X, Jin S. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 2010;182:1857-1862.
143. Boyapati SM, Shu XO, Ruan ZX, et al. Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2005;92:11-17. (Pubitemid 40875073)
144. Hargreaves DF, Patten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endo Metab 1999;84:4017-4024. (Pubitemid 30648799)
145. Sartippour MR, Rao JY, Apple S, et al. A pilot clinical study of shortterm isoflavone supplements in breast cancer patients. Nutr Cancer 2004;49:59-65. (Pubitemid 39299127)
146. Maskarinec G, Verheus M, Steinberg FM, et al. Various doses of soy isoflavones do not modify mammographic density in postmenopausal women. J Nutr 2009;139:981-986.
147. Kayisli UA, Aksu CA, Berkkanoglu M, Arici A. Estrogenicity of isoflavones on human endometrial stromal and glandular cells. J Clin Endocrinol Metab 2002;87:5539-5544. (Pubitemid 36034357)
148. Jefferson WN, Padilla-Banks E, Clark G, Newbold RR. Assessing estrogenic activity of phytochemicals using transcriptional activation and immature mouse uterotrophic responses. J Chromatogr B Analyt Technol Biomed Life Sci 2002;777:179-189. (Pubitemid 35257871)
149. Wood CE, Barnes S, Cline JM. Phytoestrogen Actions in the Breast and Uterus. In: Gilani GS, Anderson JJB, eds. Phytoestrogens and Health. Champaign, IL: AOCS Press, 2002:440-469.
150. Newbold RR, Banks EP, Bullock B, Jefferson WN. Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer Res 2001;61:4325-4328. (Pubitemid 32685752)
151. Moggs JG, Ashby J, Tinwell H, et al. The need to decide if all estrogens are intrinsically similar. Environ Health Perspect 2004;112:1137-1142. (Pubitemid 39157612)
152. Phrakonkham P, Chevalier J, Desmetz C, et al. Isoflavonoid-based bone-sparing treatments exert a low activity on reproductive organs and on hepatic metabolism of estradiol in ovariectomized rats. Toxicol Appl Pharmacol 2007;224:105-115. (Pubitemid 47494513)
153. Cline JM, Franke AA, Register TC, Golden DL, Adams MR. Effects of dietary isoflavone aglycones on the reproductive tract of male and female mice. Toxicol Pathol 2004;32:91-99. (Pubitemid 38249996)
154. Wood CE, Appt SE, Clarkson TB, et al. Effects of high-dose soy isoflavones and equol on reproductive tissues in female cynomolgus monkeys. Biol Reprod 2006;75:477-486. (Pubitemid 44268082)
155. Bandera EV, Williams MG, Sima C, et al. Phytoestrogen consumption and endometrial cancer risk: a population based case-control study in New Jersey. Cancer Causes Control 2009;20:1117-1127.
156. Horn-Ross PI, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 2003;95:1158-1164. (Pubitemid 37045394)
157. (Erratum in: J Natl Cancer Inst 2006;98:1501).
158. Xu WH, Zheng W, Xiang YB, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. BMJ 2004;328:1285.
159. Bandera EV, Kushi LH, Gifkins DM, Moore DF, McCullough M. The association between food, nutrition, and physical activity and the risk of endometrial cancer and underlying mechanisms. In: Second Report on Food, Nutrition, Physical Activity and the Prevention of Cancer, A Global Perspective. World Cancer Research Fund International, 2007. www.wcrf.org.
160. Murray MJ, Meyer WR, Lessey BA, Oi RH, DeWire RE, Fritz MA. Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. Menopause 2003;10:456-464.
161. Palacios S, Pornel B, Bergeron C, et al. Endometrial safety assessment of a specific and standardized soy extract according to international guidelines. Menopause 2007;14:1006-1011. (Pubitemid 350098660)
162. Rosario A, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebocontrolled study. Menopause 2007;14:648-655. (Pubitemid 47051957)
163. Rosario A, Cannatta ML, Marini H, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium: a 2-year randomized, double-blind, placebo-controlled study. Menopause 2009; 16:301-306.
164. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized double-blind, placebo-controlled study. Fertil Steril 2004;82:145-148. (Pubitemid 38968790)
165. Blair HC, Jordan SE, Peterson TG, Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 1996;61:629-637. (Pubitemid 26240141)
166. Cai DJ, Zhao Y, Glasier J, et al. Comparative effect of soy protein, soy isoflavones and 17beta-estradiol on bone metabolism in adult ovariectomized rats. J Bone Miner Res 2005;20:828-839. (Pubitemid 40571640)
167. Register TC, Jayo MJ, Anthony MS. Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys. J Clin Endocrinol Metab 2003;88:4362-4370. (Pubitemid 37153744)
168. Fujioka M, Uehara M, Wu J, et al. Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice. J Nutr 2004;34;2623-2627. (Pubitemid 39315263)
169. Arjmandi BH, Alekel L, Hollis B, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 1996;126:161-167. (Pubitemid 26030645)
170. Fanti P, Monier-Faugere MC, Geng Z, et al. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int 1998;8:274-281. (Pubitemid 28427078)
171. Ishimi Y, Arai N, Wang X, et al. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000;274:697-701. (Pubitemid 30663681)
172. Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Endocrinol Metab 1998;83: 2223-2235. (Pubitemid 28503006)
173. Greendale GA, FitzGerald G, Huang MH, et al. Dietary soy isoflavones and bone mineral density: results from the Study of Women's Health Across the Nation. Am J Epidemiol 2002;155:746-754. (Pubitemid 34297655)
174. Vupadhyayula PM, Gallagher JC, Templin T, Logsdon SM, Smith LM. Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal womenVa 2-year randomized, double-blind, placebo-controlled trial. Menopause 2009;16:320-328.
175. Wong WW, Lewis RD, Steinberg FM, et al. Soy isoflavone supplementation and bone mineral density in menopausal women: A 2-y multicenter clinical trial. Am J Clin Nutr 2009;90:1433-1439.
176. Alekel DL, Van Loan MD, Koehler KJ, et al. The soy isoflavones for reducing bone loss (SIRBL) study: A 3-y randomized controlled trial in postmenopausal women. Am J Clin Nutr 2010;91:218-230.
177. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 2007;146:839-847. (Pubitemid 351650484)
178. Wu J, Oka J, Ezaki J, et al. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause 2007;14: 866-874. (Pubitemid 47517585)
179. Tousen Y, Ezaki J, Fujii Y, Ueno T, Nishimuta M, Ishimi Y. Natural S-equol decreased bone resorption in postmenopausal, equol nonproducing Japanese women: a pilot randomized placebo-controlled trial. Menopause 2011;18:563-574.
180. Weaver CM, Martin BR, Jackson GS, et al. Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab 2009;94:3798-3805.
181. Zhang X, Shu XO, Li H, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 2005;165:1890-1895. (Pubitemid 41352084)
182. Koh WP, Wu AH, Wang R, et al. Gender-specific associations between soy and risk of hip fracture in the Singapore Chinese Health Study. Am J Epidemiol 2009;170:901-909.
183. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-870. (Pubitemid 27089735)
184. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263. (Pubitemid 28513713)
185. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Molec Biol 1998;64:187-191. (Pubitemid 28200991)
186. Makela S, Savolainen H, Aavik E, et al. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci USA 1999;96:7077-7082. (Pubitemid 29275012)
187. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001;24:351-356. (Pubitemid 32377601)
188. Anthony MS, Clarkson TB, Williams JK. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr 1998;68(Suppl): 1390S-1393S. (Pubitemid 28550918)
189. Anthony MS, Blair RM, Clarkson TB. Neither isoflavones nor the alcohol-extracted fraction added to alcohol-washed soy protein isolate restores the lipoprotein effects of soy protein isolate. J Nutr 2002;132:583S.
190. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001;86:41-47. (Pubitemid 32109773)
191. Dewell A, Hollenbeck PLW, Hollenbeck CB. A critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab 2006;91: 772-780. (Pubitemid 43357735)
192. Greaves KA, Wilson MD, Rudel LL, Williams JK, Wagner JD. Consumption of soy protein reduces cholesterol absorption compared to casein protein alone or supplemented with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgus monkeys. J Nutr 2000;130:820-826. (Pubitemid 30173668)
193. Taku K, Lin N, Cai D, et al. Effects of soy isoflavone extract supplements on blood pressure in adult humans: systematic review and metaanalysis of randomized placebo-controlled trials. J Hypertension 2010;28:1971-1982.
194. Hwang J, Sevanian A, Hodis HN, Ursini F. Synergistic inhibition of LDL oxidation by phytoestrogens and ascorbic acid. Free Rad Biol Med 2000;29:79-89. (Pubitemid 30658140)
195. Hwang J, Wang J, Morazzoni P, Hodis HN, Sevanian A. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Rad Biol Med 2003;34:1271-1282. (Pubitemid 36513970)
196. Register TC, Cann JA, Kaplan JR, et al. Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J Clin Endocrinol Metab 2005;90: 1734-1740. (Pubitemid 40464046)
197. Nagarajan S. Mechanisms of anti-atherosclerotic functions of soy-based diets. J Nutr Biochem 2010;21:255-260.
198. Register TC. Primate models in women's health: inflammation and atherogenesis in female cynomolgus macaques (Macaca fascicularis). Am J Primatol 2009;71:766-775.
199. Jenkins DJA, Kendall CWC, Faulkner D, et al. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 2002;51:1596-1604. (Pubitemid 36018835)
200. Hecker KD. Effects of dietary animal and soy protein on cardiovascular disease risk factors. Curr Athero Rep 2001;3:471-478.
201. Erdman JW. AHA Science Advisory: Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 2000;102:2555-2559.
202. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006;113:1034-1044. (Pubitemid 43879479)
203. Anderson JW, Johnstone BM, Cook-Newell ML. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333:276-282.
204. Lichtenstein AH, Jalbert SM, Adlercreutz H, et al. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol 2002;22:1852-1858. (Pubitemid 35315772)
205. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women. JAMA 2004;292:65-74. (Pubitemid 38923795)
206. Allen JK, Becker DM, Kwiterovich PO, Lindenstruth KA, Curtis C. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause 2007;14:106-114. (Pubitemid 46072011)
207. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997;17: 3392-3398. (Pubitemid 28028547)
208. Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr 2001;73:225-231. (Pubitemid 32109850)
209. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002;88:S39-S49. (Pubitemid 35251942)
210. Clerici C, Setchell KD, Battezzati PM, et al. Pasta naturally enriched with isoflavone agylcons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr 2007;137:2270-2278. (Pubitemid 47529589)
211. Vafeiadou K, Hall WL, Williams CM. Does genotype and equolproduction status affect response to isoflavonesi Data from a pan- European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women. Proc Nutr Soc 2006;65:106-115. (Pubitemid 43262977)
212. Thorp AA, Howe PR, Mori TA, et al. Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers. Am J Clin Nutr 2008;88:298-304.
213. Tormala R, Appt S, Clarkson TB, et al. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation. Atherosclerosis 2008;198:174-178. (Pubitemid 351419209)
214. Brinton RD. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends Pharmacol Sci 2009;30:212-222.
215. Herrick SP, Waters EM, Drake CT, McEwen BS, Milner TA. Extranuclear estrogen receptor beta immunoreactivity is on doublecortincontaining cells in the adult and neonatal rat dentate gyrus. Brain Res 2006;1121:46-58. (Pubitemid 44708881)
216. Milner TA, Ayoola K, Drake CT, et al. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J Comp Neurol 2005;491:81-95. (Pubitemid 41263413)
217. Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, McEwen BS. Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol 2008;29:219-237.
218. Milner TA, Lubbers LS, Alves SE, McEwen BS. Nuclear and extranuclear estrogen binding sites in the rat forebrain and autonomic medullary areas. Endocrinology 2008;149:3306-3312. (Pubitemid 351919599)
219. Liu F, Day M, Muniz LC, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci 2008;11:334-343. (Pubitemid 351311804)
220. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25. (Pubitemid 38967392)
221. Hogervorst E, Mursjid F, Priandini D, et al. Borobudur revisited: Soy consumption may be associated with better recall in younger, but not in older, rural Indonesian elderly. Brain Res 2011;1379:206-212.
222. Zhao L, Brinton RD. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother 2007;7:1549-1564. (Pubitemid 350106834)
223. Zhao L, Mao Z, Brinton RD. A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology 2009;150: 770-783.
224. Hamilton RT, Rettberg JR, Mao Z, et al. Hippocampal responsiveness to 17beta-estradiol and equol after long-term ovariectomy: Implication for a therapeutic window of opportunity. Brain Res 2011;1379:11-22.
225. Zhao L, Chen Q, Brinton RD. Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. Exp Biol Med 2002;227:509-519.
226. Duffy R, Wiseman H, File SE. Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav 2003;75:721-729. (Pubitemid 36936904)
227. File SE, Hartley DE, Elsabagh S, Duffy R, Wiseman H. Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause 2005;12:193-201. (Pubitemid 40464288)
228. Casini ML, Marelli G, Papaleo E, Ferrari A, DAmbrosio F, Unfer V. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril 2006;85:972-978.
229. Fournier LR, Ryan Borchers TA, Robison LM, et al. The effects of soy milk and isoflavone supplements on cognitive performance in healthy, postmenopausal women. J Nutr Health Aging 2007;11:155-164. (Pubitemid 46725291)
230. Kritz-Silverstein D, Von Muhlen D, Barrett-Connor E, Bressel MA. Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study. Menopause 2003;10: 196-202. (Pubitemid 36706302)
231. Ho SC, Chan AS, Ho YP, et al. Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. Menopause 2007;14: 489-499.